SUBSCRIBE
SUBSCRIBE

Roche

NEWS
ASCO Drugs To Watch
October 19, 2005
 · 
1 min read
Drug Development
Antisoma’s Stock Falls On Phase III Miss With R1549
October 19, 2005
 · 
1 min read
Medicine’s Two-Headed Watchdog
October 19, 2005
 · 
1 min read
Policy
U.S. FDA Looks At Anemia Drugs, Cancer Risks
October 19, 2005
 · 
1 min read
Orlistat Inhibits Cancer Growth
October 19, 2005
 · 
2 min read
New Pill Helps Breast Cancer Care
October 19, 2005
 · 
1 min read
Deals
Paper: Novartis Eyes Big U.S. Acquisition
October 19, 2005
 · 
1 min read
Deals
Bayer AG, Others Eyeing Roche OTC Business; 2-3 Billion Swiss Francs (US $1.6-$2.4 Billion)
October 19, 2005
 · 
1 min read
Deals
Top 2003 Stories From The BioSpace NewsBeat
October 19, 2005
 · 
1 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Roche receives CE mark for new blood test to detect Alzheimer’s pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
May 12, 2026
 · 
10 min read
Press Releases
Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics
May 7, 2026
 · 
4 min read
Press Releases
Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026
April 30, 2026
 · 
15 min read
Press Releases
Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026
April 30, 2026
 · 
11 min read
Press Releases
Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management
April 29, 2026
 · 
6 min read
Press Releases
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc
April 23, 2026
 · 
20 min read
Press Releases
Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
April 22, 2026
 · 
15 min read
Press Releases
Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS
April 22, 2026
 · 
10 min read
Press Releases
Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD
April 22, 2026
 · 
12 min read
Press Releases
Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
April 21, 2026
 · 
9 min read
Load More